<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04044898</url>
  </required_header>
  <id_info>
    <org_study_id>F0014-ALA-201811</org_study_id>
    <nct_id>NCT04044898</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety of ALA in Acne Vulgaris</brief_title>
  <official_title>A Pharmacokinetics and Safety Study of Aminolevulinic Acid Hydrochloride Topical Powder in Subjects With Moderate to Severe Facial Acne Vulgaris.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the pharmacokinetics and safety of ALA in patients with moderate and&#xD;
      severe acne vulgaris after single dose in different dosages.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 12, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>24 hours postdose</time_frame>
    <description>pharmacokinetic parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve [AUC]</measure>
    <time_frame>24 hours postdose</time_frame>
    <description>pharmacokinetic parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>24 hours postdose</time_frame>
    <description>pharmacokinetic parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life Time [T1/2]</measure>
    <time_frame>24 hours postdose</time_frame>
    <description>pharmacokinetic parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance [CL]</measure>
    <time_frame>24 hours postdose</time_frame>
    <description>pharmacokinetic parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution [Vd]</measure>
    <time_frame>24 hours postdose</time_frame>
    <description>pharmacokinetic parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration [Cmax](after deduction of background)</measure>
    <time_frame>24 hours postdose</time_frame>
    <description>pharmacokinetic parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve [AUC](after deduction of background)</measure>
    <time_frame>24 hours postdose</time_frame>
    <description>pharmacokinetic parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax(after deduction of background)</measure>
    <time_frame>24 hours postdose</time_frame>
    <description>pharmacokinetic parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life Time [T1/2](after deduction of background)</measure>
    <time_frame>24 hours postdose</time_frame>
    <description>pharmacokinetic parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance [CL](after deduction of background)</measure>
    <time_frame>24 hours postdose</time_frame>
    <description>pharmacokinetic parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution [Vd](after deduction of background)</measure>
    <time_frame>24 hours postdose</time_frame>
    <description>pharmacokinetic parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>2 days postdose</time_frame>
    <description>Number of participants with treatment related adverse events as assessed by physical examination, vital signs, clinical laboratory values, local skin responses</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">19</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALA 5%</intervention_name>
    <description>prepare 5% ALA solution, apply topically to the affected area for 1.5 hours, single dose</description>
    <arm_group_label>Low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALA 10%</intervention_name>
    <description>prepare 10% ALA solution, apply topically to the affected area for 3 hours, single dose</description>
    <arm_group_label>High dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects between 18 and 45 years of age (all subjects are male in&#xD;
             pilot study);&#xD;
&#xD;
          2. Diagnosis of moderate to severe facial acne vulgaris by the clinician according to the&#xD;
             Pillsbury International Improvement Classification III-IV criteria;&#xD;
&#xD;
          3. Body weight≥50 kg, body mass index (BMI) ≥19 and ≤28 kg/m2；&#xD;
&#xD;
          4. Subjects (including male subjects) voluntarily adopt effective physical contraception&#xD;
             from 14 days prior to the use of the study drug to 1 month after the end of the study,&#xD;
             and have no fertility or donation of sperm/egg plan;&#xD;
&#xD;
          5. Subjects voluntarily sign informed consent forms after being informed of the study&#xD;
             procedures，requirements and possible adverse reactions of the study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Suffer from allergic diseases ，suspect or known to have porphyrin disease or known to&#xD;
             be allergic to test medication and/or porphyrin， or allergic persons (such as&#xD;
             allergies to two or more drugs, food or pollen);&#xD;
&#xD;
          2. Allergies to visible light&#xD;
&#xD;
          3. Secondary acne patients, such as acne caused by occupational acne and corticosteroids.&#xD;
&#xD;
          4. Suffering from malignant tumors and suffering from diseases such as heart, endocrine,&#xD;
             blood, liver, immunity, metabolism, urinary system, lungs, nervous system,&#xD;
             rheumatism/joint, mental, kidney, etc led the researchers to believe that the subject&#xD;
             is not suitable for participating in this study&#xD;
&#xD;
          5. Have been treated with systemic Vitamin A acid drugs therapy within 2 months before&#xD;
             the study and/or antibiotics or hormonal drugs within 4 weeks before the study&#xD;
&#xD;
          6. Used local topical vitamin A acid drugs within the 4 weeks before the study or&#xD;
             patients with topical antibiotics, glucocorticoid and other topical treatment of acne&#xD;
             drugs within the 2 weeks before the study&#xD;
&#xD;
          7. Vaccination within 4 weeks prior to the use of the study drug;&#xD;
&#xD;
          8. Severe external injuries were suffered within the first 3 months (90 days) prior to&#xD;
             the use of the study drug, or Patients who have undergone surgical treatment may&#xD;
             significantly affect the process of studying drugs in vivo or safety assessment;&#xD;
&#xD;
          9. Taked clinical trial drugs within 3 months (90 days) prior to the use of the study&#xD;
             drug, or be participating in or plan to participate in other clinical trials during&#xD;
             the study period.&#xD;
&#xD;
         10. Drinking alcohol regularly within 3 months (90 days) prior to the use of the study&#xD;
             drug (≥3 times a week, and the average drink is equivalent to 50° white wine ≥200 mL)&#xD;
             or can not quit drinking during the study, or alcohol breath test positive&#xD;
&#xD;
         11. Smoking cigarettes (more than 10 cigarettes or equivalent of tobacco per day) within 3&#xD;
             months (90 days) prior to the use of the study drug or those who cannot quit smoking&#xD;
             during the study;&#xD;
&#xD;
         12. Blood loss/blood donation more than 300 mL (except for female physiological blood&#xD;
             loss), blood transfusion or blood product use within 3 months (90 days) prior to the&#xD;
             use of the study drug, or plan to be blood donors during the study period or 1 month&#xD;
             after the end of the study l (30 days) )&#xD;
&#xD;
         13. Consumed excessively daily tea, coffee or caffeinated beverages (up to 8 cups per day,&#xD;
             200 mL per cup) within 1 month (30 days) prior to the use of the study drug;&#xD;
&#xD;
         14. Drinks or food intake excessive of alcohol or caffeine (coffee, tea, cola, chocolate,&#xD;
             etc.) within 48 hours prior to the use of the study drug ;&#xD;
&#xD;
         15. Have a history of drug abuse or positive drug abuse screening;&#xD;
&#xD;
         16. Hepatitis B surface antigen or hepatitis C virus antibody or treponema pallidum&#xD;
             antibody positive or HIV Screening positive;&#xD;
&#xD;
         17. Physical examination (except acne), Vital Signs, laboratory examination (blood&#xD;
             routine, urine routine, liver function, renal function, fasting blood glucose, blood&#xD;
             lipids, etc).and 12 lead ECG results were judged to be abnormal and clinically&#xD;
             significant by clinicians&#xD;
&#xD;
         18. Pregnant or lactating female; blood or urine pregnancy test positive&#xD;
&#xD;
         19. Have a history of blood or Needles fainting, or difficulty in collecting blood&#xD;
&#xD;
         20. Unable to complete the study for other reasons or Researchers believe that those who&#xD;
             should not be included;&#xD;
&#xD;
         21. Researchers and their relatives including spouses and children will be not allowed to&#xD;
             participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Leihong Xiang, MD</last_name>
    <phone>0086-021-52887775</phone>
    <email>flora_xiang@vip.163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Zhang, PhD</last_name>
    <phone>0086-021-52887926</phone>
    <email>Zhangj_fudan@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Huashan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cuiyun Wu, BA</last_name>
      <phone>0086-021-52888045</phone>
      <email>wucuiyun@fudan.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 1, 2019</study_first_submitted>
  <study_first_submitted_qc>August 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne vulgaris</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

